Green Planet Bioengineering Co., Ltd. income statement GPLB

Annual Quarterly

It recorded a net loss of $35,842. Diluted earnings per share were $0.00.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016	FY 2015 Dec 31, 2015
Selling, general and administrative	0 +43.2%	0 +0.8%	0 -25.0%	0 +45.6%	0 -1.2%	0 +32.5%	0 -37.0%	0 +18.9%	0 -5.1%	0 +8.0%	0 -12.0%
Pretax income	-0 -43.2%	-0 -0.8%	-0 +25.4%	-0	—	—	—	—	—	—	—
Income tax	0	0	0	0	0	0	0	0	0	0	0
Net income	-0 -43.2%	-0 -0.8%	-0 +25.4%	-0 -46.5%	-0	-0 -32.5%	-0 +37.0%	-0 -18.9%	-0 +5.1%	-0 -8.0%	-0 +12.0%
Diluted EPS	-0.00	0.00	0.00	—	—	—	—	—	—	—	—
Weighted average shares, diluted	20	20 +0.0%	20	—	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: GPLB (OTC)
Fiscal year ends: December 31
Headquarters: Aventura, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1392449
Former names: Mondo Acquisition II, Inc. (until Oct 9, 2008)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.